➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Harvard Business School
Baxter
Express Scripts
Merck

Last Updated: July 28, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,999,999


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,999,999 protect, and when does it expire?

Patent 8,999,999 protects IMBRUVICA and is included in two NDAs.

This patent has forty-two patent family members in seventeen countries.

Summary for Patent: 8,999,999
Title:Use of inhibitors of Bruton's tyrosine kinase (Btk)
Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
Inventor(s): Buggy; Joseph J. (Mountain View, CA), Elias; Laurence (Berkeley, CA), Fyfe; Gwen (San Francisco, CA), Hedrick; Eric (Summit, NJ), Loury; David J. (San Jose, CA), Mody; Tarak D. (Sunnyvale, CA)
Assignee: Pharmacyclics, Inc. (Sunnyvale, CA)
Application Number:13/747,322
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,999,999
Patent Claim Types:
see list of patent claims
Use; Delivery; Dosage form;

Drugs Protected by US Patent 8,999,999

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pharmacyclics Inc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-002 Dec 20, 2017 AB RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT OF SMALL LYMPHOCYTIC LEUKEMIA ⤷  Free Forever Trial
Pharmacyclics Inc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-002 Dec 20, 2017 AB RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA ⤷  Free Forever Trial
Pharmacyclics Inc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-002 Dec 20, 2017 AB RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA ⤷  Free Forever Trial
Pharmacyclics Inc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-001 Nov 13, 2013 AB RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA ⤷  Free Forever Trial
Pharmacyclics Inc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-001 Nov 13, 2013 AB RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,999,999

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2011261185 ⤷  Free Forever Trial
Australia 2015275321 ⤷  Free Forever Trial
Australia 2018204179 ⤷  Free Forever Trial
Australia 2020202752 ⤷  Free Forever Trial
Brazil 112012030625 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Baxter
Moodys
Mallinckrodt
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.